Article Information
History
- May 27, 2021.
Article Versions
- Version 1 (January 15, 2021 - 11:14).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Michael Hultström1,2,
- Karin Fromell3,
- Anders Larsson4,
- Susan E Quaggin5,6,
- Christer Betsholtz3,7,
- Robert Frithiof1,
- Miklos Lipcsey1,8 and
- Marie Jeansson3,7,*
- 1Anaesthesiology and Intensive Care Medicine, Department of Surgical Sciences, Uppsala University, Sweden
- 2Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Sweden
- 3Department of Immunology, Genetics, and Pathology, Uppsala University, Sweden
- 4Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sweden
- 5Feinberg Cardiovascular Research Institute, Northwestern University, Chicago, IL, USA
- 6Division of Nephrology and Hypertension, Northwestern University, Chicago, IL, USA
- 7Department for Medicine, Huddinge, Karolinska Institutet, Sweden
- 8Hedenstierna Laboratory, CIRRUS, Anaesthesiology and Intensive Care Medicine, Department of Surgical Sciences, Uppsala University, Sweden
- ↵*Corresponding author:
Marie Jeansson, marie.jeansson{at}ki.se
Posted May 27, 2021.
Elevated Angiopoietin-2 inhibits thrombomodulin-mediated anticoagulation in critically ill COVID-19 patients
